Humacyte (NASDAQ:HUMA) versus Quince Therapeutics (NASDAQ:QNCX) Head-To-Head Survey

Humacyte (NASDAQ:HUMA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility & Risk

Humacyte has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Valuation and Earnings

This table compares Humacyte and Quince Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$1.57 million	302.63	-$110.78 million	($1.07)	-3.73
Quince Therapeutics	N/A	N/A	-$31.39 million	($0.84)	-1.26

Quince Therapeutics has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Humacyte and Quince Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	0	1	3	0	2.75
Quince Therapeutics	0	0	0	0	N/A

Humacyte currently has a consensus target price of $8.00, suggesting a potential upside of 100.50%. Given Humacyte’s higher possible upside, equities analysts clearly believe Humacyte is more favorable than Quince Therapeutics.

Profitability

This table compares Humacyte and Quince Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Humacyte	N/A	-199.62%	-61.45%
Quince Therapeutics	N/A	-36.36%	-28.83%

Insider and Institutional Ownership

44.7% of Humacyte shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 23.1% of Humacyte shares are held by insiders. Comparatively, 21.0% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Humacyte beats Quince Therapeutics on 6 of the 11 factors compared between the two stocks.

About Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

About Quince Therapeutics

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.